Larkspur Biosciences starts clinical study of targeted protein degrader LRK-4189 for colorectal cancer and solid tumors

Larkspur Biosciences has begun dosing in a Phase 1 clinical study of its new cancer drug candidate, LRK-4189. LRK-4189 is a first-in-class targeted protein degrader designed to treat microsatellite stable colorectal cancer and other solid tumors by targeting PIP4K2C, a key cancer cell fitness target. The study is initially enrolling healthy volunteers to assess the drug's safety, tolerability, and how it's processed by the body, with patient studies to follow.